PHASQ (PhaseBio Pharmaceuticals) 1-Year Sharpe Ratio : -1.09 (As of Jun. 27, 2025)

View and export this data going back to 2018. Start your Free Trial

What is PhaseBio Pharmaceuticals 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2025-06-27), PhaseBio Pharmaceuticals's 1-Year Sharpe Ratio is -1.09.

Competitive Comparison of PhaseBio Pharmaceuticals's 1-Year Sharpe Ratio

For the Biotechnology subindustry, PhaseBio Pharmaceuticals's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PhaseBio Pharmaceuticals's 1-Year Sharpe Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhaseBio Pharmaceuticals's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where PhaseBio Pharmaceuticals's 1-Year Sharpe Ratio falls into.

Save Embed

;

Save Embed

;

PhaseBio Pharmaceuticals 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

PhaseBio Pharmaceuticals (OTCPK:PHASQ) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

PhaseBio Pharmaceuticals 1-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of PhaseBio Pharmaceuticals's 1-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

PhaseBio Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseBio Pharmaceuticals Inc (OTCPK:PHASQ) » Definitions » 1-Year Sharpe Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Great Valley Parkway, Suite 30, Malvern, PA, USA, 19355

Website

https://www.phasebio.com

PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.

Executives

New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Glen Burkhardt	officer: VP, Human Resources	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY.,SUITE 30, MALVERN PA 19355
Jonathan Birchall	officer: Chief Commercial Officer	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN PA 19355
William D. Humphries	director	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Clay Thorp	director	C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Nancy J Hutson	director	64 MONTAUK AVENUE, STONINGTON CT 06378
Edmund Harrigan	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Caroline M Loewy	director	300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Peter Justin Klein	director	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
David James Ballance	officer: VP, Research and Sci. Affairs	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Michael York	officer: VP, Corporate Development	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
John Sang Lee	officer: Chief Medical Officer	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Susan Elizabeth Arnold	officer: VP, Preclinical and Chem	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY DRIVE, SUITE 30, MALVERN PA 19355
Kristopher Hanson	officer: VP, Head of Legal	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355